| 名称 | Methacycline hydrochloride |
| 描述 | Methacycline hydrochloride (Rondomycin) is a broad-spectrum semisynthetic antibiotic related to TETRACYCLINE but excreted more slowly and maintaining effective blood levels for a more extended period. |
| 体外活性 | Methacycline, within pulmonary alveolar macrophages, does not alter the response gene of TGF-β1 nor attenuates the aggregation of inflammatory cells. Following tracheal aspiration of bleomycin, intraperitoneal injection of Methacycline at 100 mg/kg, starting on day 10, enhances survival rates by day 17. Methacycline mitigates bleomycin-induced classical EMT (Epithelial-Mesenchymal Transition) markers, including SNAIL1, TWIST1, type I collagen, fibronectin, and their mRNA expressions. |
| 体内活性 | Methacycline inhibits the TGF-β1-induced non-Smad signaling pathways, including the activation of c-Jun N-terminal kinase (JNK), p38, and Akt, without suppressing Smad or β-catenin transcriptional activities. It does not affect the baseline activities of JNK, p38, or Akt, nor the TGF-β1 response of lung fibroblasts. Additionally, methacycline inhibits the TGF-β1-induced expression of α-smooth muscle actin (α-SMA), SNAIL1, and type I collagen in primary alveolar epithelial cells. |
| 存储条件 | keep away from direct sunlight,store under nitrogen | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | DMSO : 27.5 mg/mL (57.43 mM)
|
| 关键字 | fibrosis | fibrogenesis | c-Jun | TGF-β1 | Methacycline | N-terminal | Inhibitor | p38 | inhibit | Methacycline hydrochloride | Bacterial | epithelial-mesenchymal | Antibiotic | kinase | Smad | transition | EMT | pulmonary | Methacycline Hydrochloride | Akt |
| 相关产品 | Neomycin sulfate | Dimethyl sulfoxide |
| 相关库 | FDA上市及药典收录分子库 | 经典已知活性库 | 药物功能重定位化合物库 | 抑制剂库 | 微生物天然产物库 | FDA 上市药物库 | 已知活性化合物库 |
United States
